Sibylle Loibl
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis(2014)4,585 cited
- → Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013(2013)3,672 cited
- → The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014(2014)3,065 cited
- → Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes(2012)2,632 cited
- → Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer(2018)2,536 cited
- → Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer(2019)2,463 cited
- → Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy(2017)2,068 cited
- → Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer(2009)1,771 cited
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial(2020)1,743 cited
- → Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer(2021)1,582 cited